The well-known psychiatric manual, often referred to as “the Bible of psychiatry,” is set for a significant update.
The American Psychiatric Association (APA) publishes the DSM-5, which stands for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition.
Recently, the APA shared its vision for the next revision through five studies released in The American Journal of Psychiatry.
Rather than being a hefty book, the new DSM will be an online “living document,” easy to update. While the APA hasn’t set a specific timeline or decided on a name, whether it will be called DSM-6 or something else is still uncertain. They are looking for feedback from a wide range of mental health professionals and individuals with psychiatric conditions.
“The DSM is fundamentally the basis for mental health diagnosis,” said Dr. Maria Oquendo, who chairs the Strategic Committee focused on the manual’s future, during a press conference that introduced the supportive research.
This manual is crucial for psychiatrists, psychologists, medical professionals, researchers, and insurance companies.
“It helps in understanding the patient’s situation more accurately,” explained Dr. Jennifer Havens, who chairs child and adolescent psychiatry at NYU Grossman School of Medicine. “The core task in any illness is to diagnose it accurately, because that’s how you start the right treatments.”
Staying Up-to-Date
Traditionally, the DSM has been updated about every 15 years, with the most recent version released in 2013. “Every revision reflects new scientific insights, clinical practices, and cultural awareness,” noted Oquendo.
However, the lengthy revision process and the print format have limitations, as pointed out by Dr. Nitin Gogtay, deputy medical director of the APA, who spoke at the virtual press conference.
“Clinicians and others might not have timely access to the latest evidence, which can delay the adoption of new findings in practice,” he remarked. “Our aim is to keep this process as up-to-date as possible.”
Shifting to an online format will allow more frequent updates reflecting scientific advancements in diagnosing and treating mental illnesses.
Responding to Critiques of the DSM
Many forthcoming changes in the manual aim to include scientific advancements related to mental disorders, their diagnosis, and treatment, while addressing common criticisms of the current DSM.
“Understanding the reasons behind an illness is standard in medicine,” suggests Havens, who is not involved in the revisions. “If we grasp the causes, we might prevent them. It also impacts our treatment approaches.”
Due to the complexity of mental illness causes—encompassing genetics, biology, environment, and life experiences—previous DSM versions largely omitted them. The DSM-5, however, acknowledged potential causes as “Risk and Prognostic Factors.”
Failing to consider underlying causes can affect diagnosis and treatment plans, according to Havens. For instance, childhood trauma significantly impacts mental health.
“Trauma contributes greatly to the mental illnesses we encounter,” she stated. “It severely heightens vulnerability to serious conditions like schizophrenia. This reflects a gap in our understanding, and we need to intervene more effectively.”
Now, researchers have gained a better grasp of the factors that can trigger or worsen mental illnesses, which will be included in future versions of the DSM and in prevention strategies.
Oquendo highlighted issues like poverty, exposure to environmental toxins, and belonging to a marginalized community as factors that can negatively impact mental health.
Therefore, future DSMs will stress elements that influence mental health and present strategies for symptom prevention across various populations.
This shift represents a “transformative change in psychiatry,” says Havens.
The Role of Biological Markers
Since the DSM-5 was released, there have been substantial advancements in understanding the biological roots of mental health disorders, leading researchers closer to identifying biological markers.
“These could range from blood tests and neuroimaging tests to digital assessments from wearable technology that evaluate biological processes underlying mental disorders,” explains Dr. Jonathan Alpert, vice chair of the Future DSM Steering Committee of the APA and head psychiatrist at Montefiore Medical Center in New York City.
The FDA has already approved tests for biomarkers related to Alzheimer’s disease, according to Alpert.
“There are blood tests and tests of cerebrospinal fluid that identify specific proteins,” he noted.
Looking ahead, certain markers of inflammation may emerge as biological indicators for major depression.
“Some individuals with major depressive disorder show heightened inflammatory markers, which can even be detected by a blood test for C-reactive protein (CRP),” Alpert explained. This marker is indicative of inflammation.
Interestingly, these individuals may respond better to anti-inflammatory treatments, either alone or alongside typical antidepressants like SSRIs.
Discussions around population-based benefits of such testing might appear in future iterations of the DSM.
Voices of Lived Experience
Currently, the APA is soliciting feedback on its approaches and strategies from various stakeholders, including healthcare providers, advocates, and individuals living with mental health issues. They aim for the next edition to be shaped by a broader range of voices beyond just psychiatrists.
“There’s a strong acknowledgment that previous versions of this document lacked diverse input,” remarked Dr. Tami Benton, who leads child and adolescent psychiatry at the Children’s Hospital of Philadelphia, and is part of the DSM strategic committee. “Greater inclusion of affected individuals—those with lived experience, including adolescents and their families—will be essential.”
